Samchundang Pharm gains FDA feedback on oral semaglutide generic path

Samchundang Pharm received FDA Pre-ANDA guidance on its oral semaglutide generic development, reducing regulatory uncertainty though final approval remains subject to subsequent ANDA review. The South Korean manufacturer has already signed supply contracts in the US and Europe and is pursuing regulatory consultations in Japan and the Middle East.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.